These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 19090867)

  • 41. Past, present, and future of chronic kidney disease anemia management in the United States.
    Wish JB
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):101-8. PubMed ID: 19233069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.
    Sikand H; Decter A; Greco T; Watson SH; Kang YJ; Mody SH; Piech CT; Duh MS; Naeem A
    Ann Pharmacother; 2008 Jan; 42(1):16-23. PubMed ID: 18029428
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correcting iron-restricted erythropoiesis and improving anemia in patients on hemodialysis: practical tips that can make a difference.
    Easom A
    Nephrol Nurs J; 2009; 36(5):529-37, 553. PubMed ID: 19856814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Costs of chronic dialysis in a public hospital: myths and realities].
    Lamas J; Alonso M; Saavedra J; García-Trío G; Rionda M; Ameijeiras M
    Nefrologia; 2001; 21(3):283-94. PubMed ID: 11471309
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice.
    Sanz-Granda A
    Farm Hosp; 2009; 33(4):208-16. PubMed ID: 19712609
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.
    Chacón-Araya M; Rey-Rodríguez D; Rodríguez De León F; Ramos-Esquivel A; Sunning T
    J Med Econ; 2019 Aug; 22(8):736-741. PubMed ID: 30915883
    [No Abstract]   [Full Text] [Related]  

  • 47. Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study.
    Shigematsu T; Takami H; Shimizu T; Shimoyama H; Kim S; Hirose S; Sakai T; Kono T; Mochizuki T; Nishio K; Degawa H; Motomiya Y
    Ther Apher Dial; 2008 Dec; 12(6):469-74. PubMed ID: 19140845
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data.
    Carrera F; Disney A; Molina M
    Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv19-iv30. PubMed ID: 17526546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial].
    Saglimbene V; D'Alonzo D; Ruospo M; Vecchio M; Natale P; Gargano L; Nicolucci A; Pellegrini F; Craig JC; Triolo G; Procaccini DA; Santoro A; Di Giulio S; La Rosa S; Murgo A; Di Toro Mammarella R; Sambati M; D'Ambrosio N; Greco V; Giannoccaro G; Flammini A; Boccia E; Montalto G; Pagano S; Amarù S; Fici M; Lumaga GB; Mancini E; Veronesi M; Patregnani L; Querques M; Schiavone P; Chimienti S; Palumbo R; Di Franco D; Della Volpe M; Gori E; Salomone M; Iacono A; Moscoloni M; Treglia A; Casu D; Piras AM; Di Silva A; Mandreoli M; Lopez A; Quarello F; Catizone L; Russo G; Forcellini S; Maccarone M; Catucci G; Di Paolo B; Stingone A; D'Angelo B; Guastoni C; Pasquali S; Minoretti C; Bellasi A; Boscutti G; Martone M; David S; Schito F; Urban L; Di Iorio B; Caruso F; Mazzoni A; Musacchio R; Andreoli D; Cossu M; Li Cavoli G; Cornacchiari M; Granata A; Clementi A; Giordano R; Guastoni C; Barzaghi W; Valentini M; Hegbrant J; Tognoni G; Strippoli GF
    G Ital Nefrol; 2013; 30(2):. PubMed ID: 23832463
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduced drug costs from switching hemodialysis patients from epoetin alfa in multidose vials to pre-filled syringes.
    Wazny LD; Raymond CB; Do MK; Skwarchuk DE
    CANNT J; 2009; 19(3):39-41. PubMed ID: 19899498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Economic and organizational impact of the changing hospital funding practices of erythropoiesis-stimulating agents on the management of care of dialysis patients in France.
    Therasse C; Fusier I; Cordonnier AL; Bérard F; de Curzon OP; Bocquet F; Paubel P
    J Comp Eff Res; 2018 Jun; 7(6):569-580. PubMed ID: 29537304
    [TBL] [Abstract][Full Text] [Related]  

  • 52. No associations between prolactin concentrations and response to erythropoiesis-stimulating agents in hemodialysis patients.
    Riegersperger M; van Houte M; Födinger M; Wojcik J; Hörl WH; Winkelmayer WC; Sunder-Plassmann G
    Am J Nephrol; 2007; 27(4):390-6. PubMed ID: 17587788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of anemia in clinic patients with heart failure and cost analysis of epoetin treatment.
    Choy CK; Spencer AP; Nappi JM
    Pharmacotherapy; 2007 May; 27(5):707-14. PubMed ID: 17461706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Financial impact of anemia in patients with chronic renal insufficiency undergoing hemodialysis at centers].
    Rousseau P
    Nephrologie; 1990; 11(3):147-52. PubMed ID: 2234271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients.
    Stephens JM; Emerson LC; Spry LA; Caloyeras JP; Anderson ER; Reitan JF; Ashfaq A
    Curr Med Res Opin; 2016; 32(2):313-20. PubMed ID: 26583202
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
    McGahan L
    Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dialysis adequacy and response to erythropoiesis-stimulating agents: what is the evidence base?
    Locatelli F; Del Vecchio L; Pozzoni P; Andrulli S
    Semin Nephrol; 2006 Jul; 26(4):269-74. PubMed ID: 16949464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anaemia in older people with chronic heart failure: The potential cost.
    Man-Fai Sim V; Nam MC; Riley S; Yousef Z; Hurley J; Cheung WY; O'Mahony S
    Technol Health Care; 2009; 17(5-6):377-85. PubMed ID: 20051617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of ESA use in the non-dialysis chronic kidney disease population with anemia.
    Collins AJ; Guo H; Gilbertson DT; Bradbury BD
    Nephron Clin Pract; 2009; 111(2):c141-8. PubMed ID: 19147996
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: a retrospective claims database analysis.
    Wish J; Schulman K; Law A; Nassar G
    Kidney Blood Press Res; 2009; 32(2):110-8. PubMed ID: 19372704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.